Medidata, the leading global provider of cloud-based solutions for clinical research in life sciences, announced recently that Techfields Pharma has selected the Medidata Clinical Cloud to power a Phase II Ischemic Stroke study.
“The China-based pharmaceutical company will leverage Medidata’s robust study management capabilities and mobile health (mHealth) technology to optimize trial processes and gather new insights on treatment efficacy and patients’ quality of life,” a provided statement reads.
“Cloud and mobile health technologies offer new channels for maximizing the value of clinical data, and we believe they will play an increasingly important role in our ability to bring vital new medicines to patients,” said Dr. Chongxi Yu, Techfields’ founder and president. “Using the Medidata platform, our research teams can more quickly access richer, more complete clinical datasets while gaining valuable insight into patient well-being and disease progression. This is a key focus of our R&D strategy, as we pursue promising drug candidates with the potential to help people live longer, healthier lives.”
Headquartered in Suzhou, China, Techfields is a clinical-stage pharmaceutical company focused on the development of novel medicines for inflammatory, autoimmune, cardiovascular, metabolic and aging-related diseases, as well as depression.